

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/006711

International filing date: 02 March 2005 (02.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/549,384
Filing date: 02 March 2004 (02.03.2004)

Date of receipt at the International Bureau: 25 April 2005 (25.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1309522

UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 18, 2005


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/549,384

FILING DATE: *March 02, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/06711

Certified by



Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



"EXPRESS MAIL CERTIFICATE"16351 U.S.PTO
030204"Express Mail" Mailing Label Number **EL964434208US**Date Of Deposit: **March 2, 2004**

I Hereby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.10 On The Date Indicated Above And Is Addressed To: COMMISSIONER FOR PATENTS, MAIL STOP: PROVISIONAL APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Name Of Person Mailing Paper Or Fee

(Type Or Print) Aaron GrahamSignature Aaron Graham16356 U.S.PTO
60549384
030204**PROVISIONAL APPLICATION COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION for PATENT under 37 CFR 1.53(c).

Docket No.	PU60768P	
------------	-----------------	--

INVENTOR(s) / APPLICANT(s)			
Last Name	First Name	Middle Initial	Residence (City and Either State or Foreign Country)
YAMASHITA	Dennis	S.	Collegeville, Pennsylvania
LIN	Hong		Collegeville, Pennsylvania

TITLE OF THE INVENTION (280 characters max) INHIBITORS OF AKT ACTIVITY					
Correspondence Address: GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 709 Swedeland Road King of Prussia			Telephone No. 610-270-5023 Facsimile No. 610-270-5090		
State	PA	Zip Code	19406-0939	Country	United States of America

ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification	Number of Pages	25	Total Number of Pages = 26
<input checked="" type="checkbox"/> Abstract	Number of Pages	1	
<input type="checkbox"/> Drawings	Number of Sheets		<input type="checkbox"/> Other (specify)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 19-2570	PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00

Respectfully submitted,
Signature:

Wayne J. Dustman
Wayne J. Dustman

Date:

March 2, 2004

Registration No.:

33,870 Additional inventors are being named on separately numbered sheets attached hereto.**PROVISIONAL APPLICATION FILING ONLY**

SEND TO: Commissioner for Patents, P.O. Box 1450, Mail Stop: Patent Application, Alexandria, VA 22313-1450.

**20462**

CUSTOMER NUMBER

INHIBITORS OF AKT ACTIVITYFIELD OF THE INVENTION

This invention relates to novel pyridine compounds, the use of such
5 compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer
and arthritis.

BACKGROUND OF THE INVENTION

The present invention relates to pyridine containing compounds that are
10 inhibitors of the activity of one or more of the isoforms of the serine/threonine
kinase, Akt (also known as PKB). The present invention also relates to
pharmaceutical compositions comprising such compounds and methods of using
the instant compounds in the treatment of cancer and arthritis.

Apoptosis (programmed cell death) plays essential roles in embryonic
15 development and pathogenesis of various diseases, such as degenerative neuronal
diseases, cardiovascular diseases and cancer. Recent work has led to the
identification of various pro- and anti-apoptotic gene products that are involved in
the regulation or execution of programmed cell death. Expression of anti-apoptotic
genes, such as Bcl2 or Bcl-x_L, inhibits apoptotic cell death induced by various
20 stimuli. On the other hand, expression of pro-apoptotic genes, such as Bax or Bad,
leads to programmed cell death (Adams et al. *Science*, 281:1322-1326 (1998)).
The execution of programmed cell death is mediated by caspase -1 related
proteinases, including caspase-3, caspase- 7, caspase-8 and caspase-9 etc
(Thornberry et al. *Science*, 281:1312-1316 (1998)).

25 The phosphatidylinositol 3'-OH kinase (PI3K)/Akt/PKB pathway appears
important for regulating cell survival/cell death (Kulik et al. *Mol. Cell. Biol.* 17:1595-
1606 (1997); Franke et al, *Cell*, 88:435-437 (1997); Kauffmann-Zeh et al. *Nature*
385:544-548 (1997) Hemmings *Science*, 275:628-630 (1997); Dudek et al.,
Science, 275:661-665 (1997)). Survival factors, such as platelet derived growth
30 factor (PDGF), nerve growth factor (NGF) and insulin-like growth factor-1 (IGF-I),
promote cell survival under various conditions by inducing the activity of PI3K (Kulik
et al. 1997, Hemmings 1997). Activated PI3K leads to the production of
phosphatidylinositol (3,4,5)-triphosphate (PtdIns (3,4,5)-P3), which in turn binds to,
and promotes the activation of, the serine/ threonine kinase Akt, which contains a
35 pleckstrin homology (PH)-domain (Franke et al *Cell*, 81:727-736 (1995); Hemmings
Science, 277:534 (1997); Downward, *Curr. Opin. Cell Biol.* 10:262-267 (1998),
Alessi et al., *EMBO J.* 15: 6541-6551 (1996)). Specific inhibitors of PI3K or

dominant negative Akt/PKB mutants abolish survival-promoting activities of these growth factors or cytokines. It has been previously disclosed that inhibitors of PI3K (LY294002 or wortmannin) blocked the activation of Akt/PKB by upstream kinases. In addition, introduction of constitutively active PI3K or Akt/PKB mutants promotes 5 cell survival under conditions in which cells normally undergo apoptotic cell death (Kulik et al. 1997, Dudek et al. 1997).

Analysis of Akt levels in human tumors showed that Akt2 is overexpressed in a significant number of ovarian (J. Q. Cheung et al. *Proc. Natl. Acad. Sci. U.S.A.* 89:9267-9271(1992)) and pancreatic cancers (J. Q. Cheung et al. *Proc. Natl. Acad. Sci. U.S.A.* 93:3636-3641 (1996)). Similarly, Akt3 was found to be overexpressed 10 in breast and prostate cancer cell lines (Nakatani et al. *J. Biol. Chem.* 274:21528-21532 (1999)). It was demonstrated that AKT2 was over-expressed in 12% of ovarian carcinomas and that amplification of AKT was especially frequent in 50% of undifferentiated tumors, suggestion that AKT may also be associated with tumor 15 aggressiveness (Bellacosa, et al., *Int. J. Cancer*, 64, pp. 280-285, 1995). It has also been reported that increased levels of Akt1 activity were detected in primary carcinomas from prostate, breast, and ovary (Sun et al *Am. J. Path.* 2001, 159 (2), 431-437).

The tumor suppressor PTEN, a protein and lipid phosphatase that 20 specifically removes the 3' phosphate of PtdIns(3,4,5)-P₃, is a negative regulator of the PI3K/Akt pathway (Li et al. *Science* 275:1943-1947 (1997), Stambolic et al. *Cell* 95:29-39 (1998), Sun et al. *Proc. Nati. Acad. Sci. U.S.A.* 96:6199-6204 (1999)). Germline mutations of PTEN are responsible for human cancer syndromes such as Cowden disease (Liaw et al. *Nature Genetics* 16:64-67 (1997)). PTEN is deleted in 25 a large percentage of human tumors and tumor cell lines without functional PTEN show elevated levels of activated Akt (Li et al. supra, Guldberg et al. *Cancer Research* 57:3660-3663 (1997), Risinger et al. *Cancer Research* 57:4736-4738 (1997)).

These observations demonstrate that the PI3K/Akt pathway plays important 30 roles for regulating cell survival or apoptosis in tumorigenesis.

Three members of the Akt/PKB subfamily of second-messenger regulated serine/threonine protein kinases have been identified and termed Akt1/ PKBa, Akt2/PKB β , and Akt3/PKB γ respectively. The isoforms are homologous, particularly in regions encoding the catalytic domains. Akt/PKBs are activated by 35 phosphorylation events occurring in response to PI3K signaling. PI3K phosphorylates membrane inositol phospholipids, generating the second messengers phosphatidyl- inositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-

bisphosphate, which have been shown to bind to the PH domain of Akt/PKB. The current model of Akt/PKB activation proposes recruitment of the enzyme to the membrane by 3'-phosphorylated phosphoinositides, where phosphorylation of the regulatory sites of Akt/PKB by the upstream kinases occurs (B.A. Hemmings,

- 5 Science 275:628-630 (1997); B.A. Hemmings, Science 276:534 (1997); J. Downward, Science 279:673-674 (1998)).

Phosphorylation of Akt1/PKB α occurs on two regulatory sites, Thr³⁰⁸ in the catalytic domain activation loop and on Ser⁴⁷³ near the carboxy terminus (D. R.

Alessi et al. EMBO J. 15:6541-6551 (1996) and R. Meier et al. J. Biol. Chem.

- 10 272:30491-30497 (1997)). Equivalent regulatory phosphorylation sites occur in Akt2/PKB β and Akt3/PKB γ . The upstream kinase, which phosphorylates Akt/PKB at the activation loop site has been cloned and termed 3'-phosphoinositide dependent protein kinase 1 (PDK1). PDK1 phosphorylates not only Akt/PKB, but also p70 ribosomal S6 kinase, p90RSK, serum and glucocorticoid-regulated kinase 15 (SGK), and protein kinase C. The upstream kinase phosphorylating the regulatory site of Akt/PKB near the carboxy terminus has not been identified yet, but recent reports imply a role for the integrin-linked kinase (ILK-1), a serine/threonine protein kinase, or autophosphorylation.

Inhibition of Akt activation and activity can be achieved by inhibiting PI3K 20 with inhibitors such as LY294002 and wortmannin. However, PI3K inhibition has the potential to indiscriminately affect not just all three Akt isozymes but also other PH domain-containing signaling molecules that are dependent on PdtIns(3,4,5)-P3, such as the Tec family of tyrosine kinases. Furthermore, it has been disclosed that Akt can be activated by growth signals that are independent of PI3K.

25 Alternatively, Akt activity can be inhibited by blocking the activity of the upstream kinase PDK1. No specific PDK1 inhibitors have been disclosed. Again, inhibition of PDK1 would result in inhibition of multiple protein kinases whose activities depend on PDK1, such as atypical PKC isoforms, SGK, and S6 kinases (Williams et al. *Curr. Biol.* 10:439-448 (2000)).

30 Small molecule inhibitors of AKT are useful in the treatment of tumors with activated AKT (e.g. PTEN null tumors and tumors with ras mutations). PTEN is a critical negative regulator of AKT and its function is lost in many cancers, including breast and prostate carcinomas, glioblastomas, and several cancer syndromes including Bannayan-Zonana syndrome (Maehama, Tomohiko; Taylor, Gregory S.; Dixon, Jack E. *Annual Review of Biochemistry* 2001, 70, 247-279), Cowden disease (Parsons, Ramon; Simpson, Laura. *Methods in Molecular Biology* (Totowa, NJ, United States) 2003, 222(Tumor Suppressor Genes, Volume 1), 147-166), and

Lhermitte-Duclos disease(Backman, Stephanie A.; Stambolic, Vuk; Mak, Tak W. *Current Opinion in Neurobiology* 2002, 12(5), 516-522). AKT3 is up-regulated in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer cell lines and AKT2 is over-expressed in pancreatic and ovarian

5 carcinomas. Therefore a small molecule AKT inhibitor is expected to be useful for the treatment of these types of cancer as well as other types of cancer. AKT inhibitors are also useful in combination with existing chemotherapeutic agents.

It is an object of the instant invention to provide novel compounds that are
10 inhibitors of Akt/PKB.

It is also an object of the present invention to provide pharmaceutical compositions that comprise a pharmaceutical carrier and compounds useful in the methods of the invention.


It is also an object of the present invention to provide a method for treating
15 cancer that comprises administering such inhibitors of Akt/PKB activity.

It is also an object of the present invention to provide a method for treating arthritis that comprises administering such inhibitors of Akt/PKB activity.

20

SUMMARY OF THE INVENTION

This invention relates to compounds of Formula (I):



(I)

25 wherein:

L^1 is selected from the group consisting of a bond, -O-, -N(R^5)-, -S-, -S(O)-, -S(O₂)-, alkyl, and -N(R^5)C(O)-;

30 L^2 is selected from the group consisting of a bond, -O-, -N(R^5)-, -N(R^5)C(O)-, -S-, -S(O)-, -S(O₂)-, and -C(O)N(R^5)-;

L³ is alkyl, wherein the alkyl is substituted with one or two substituents independently selected from the group consisting of amino, oxo, and hydroxy;

5 L⁶ is selected from the group consisting of a bond, -O-, -N(R⁵)-, -S-, -S(O)-, -S(O₂)-, alkyl, and -N(R⁵)C(O)-;

R¹ is selected from the group consisting of aryl, substituted aryl, heterocycle and substituted heterocycle;

10 R² is selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, and a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the
15 aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -C(O)OR⁷, -C(O)NR⁸R⁹, -S(O)₂NR⁸R⁹, and -S(O)_nR⁷,

20 where n is 0-2,

R⁷ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and

25 R⁸ and R⁹ are independently hydrogen, cycloalkyl, C₁-C₁₂aryl, substituted cycloalkyl, substituted C₁-C₁₂aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of:
alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(O)OR¹⁰, -S(O)_nR¹⁰, -C(O)NR¹⁰R¹¹, -S(O)₂NR¹⁰R¹¹, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, and substituted aryl,
or R⁸ and R⁹ taken together with the nitrogen to which they are attached
30 represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally substituted with one or more substituents selected from amino, methylamino and dimethylamino,

35 where R¹⁰ and R¹¹ are independently hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and n is 0-2;

R³ and R⁶ are independently selected from the group consisting of hydrogen, aryl, substituted aryl, and arylalkoxy; provided that when L¹ and L² are bonds, at least one of R³ and R⁶ is other than hydrogen;

5 R⁴ is selected from the group consisting of hydrogen and halo; and

 R⁵ is selected from the group consisting of hydrogen and alkyl;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

10

This invention relates to a method of treating cancer, which comprises administering to a subject in need thereof an effective amount of an Akt/PKB inhibiting compound of Formula (I).

15

This invention relates to a method of treating arthritis, which comprises administering to a subject in need thereof an effective amount of an Akt/PKB inhibiting compound of Formula (I).

20

The present invention also relates to the discovery that the compounds of Formula (I) are active as inhibitors of Akt/PKB.

In a further aspect of the invention there is provided novel processes and novel intermediates useful in preparing the presently invented Akt/PKB inhibiting compounds.

25

Included in the present invention are pharmaceutical compositions that comprise a pharmaceutical carrier and compounds useful in the methods of the invention.

30

Also included in the present invention are methods of co-administering the presently invented Akt/PKB inhibiting compounds with further active ingredients.


DETAILED DESCRIPTION OF THE INVENTION

This invention relates to compounds of Formula (I) as described above.

35

The presently invented compounds of Formula (I) inhibit Akt/PKB activity. In particular, the compounds disclosed selectively inhibit one, two or the three Akt/PKB isoforms.

Included among the presently invented compounds of Formula (I) are those having Formula (II):



(II) (II)

5 wherein:

L^4 is selected from the group consisting of a bond, and -O-;

10 L^5 is alkyl, wherein the alkyl is substituted with one or two substituents independently selected from the group consisting of amino, oxo, and hydroxy;

R^{14} is selected from the group consisting of C₁-C₁₂aryl, and substituted C₁-C₁₂aryl;

15 R^{15} is selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, C₁-C₁₂aryl and C₁-C₁₂aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro, cyano and halogen;

20 R^{16} and R^{17} are independently selected from the group consisting of hydrogen, C₁-C₁₂aryl and substituted C₁-C₁₂aryl; and

pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

25 Included among the presently invented compounds of Formula (II) are those in which:

L^4 is selected from the group consisting of a bond, and -O-;

30 L^5 is alkyl, wherein the alkyl is substituted with one or two substituents independently selected from the group consisting of amino, oxo, and hydroxy;

R¹⁴ is selected from phenyl, pyridine, indazole, 7-azaindole, quinoline, isoquinoline, substituted phenyl, substituted pyridine, substituted indazole, substituted 7-azaindole, substituted quinoline and substituted isoquinoline;

5

R¹⁵ is selected from phenyl, pyridine, thiophene, furan, pyrrole, indazole, quinoline, isoquinoline, 7-azaindole, substituted phenyl, substituted pyridine, substituted thiophene, substituted furan, substituted indazole, substituted quinoline, substituted 7-azaindole and substituted isoquinoline;

10

R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, phenyl, pyridine, thiophene, furan, pyrrole, substituted phenyl, substituted pyridine, substituted thiophene, substituted furan, and substituted pyrrole; and

15

pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Included among the compounds useful in the present invention are:

- 20 (S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine;
(S)-1-Benzyl-2-[6-furan-2-yl-5-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;
- 25 (S)-1-Benzyl-2-[5,6-bis-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;
(S)-1-Benzyl-2-[6-thiophen-2yl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;
- 30 (S)-1-Benzyl-2-[6-(4-chlorophenyl)-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;
(S)-1-Benzyl-2-[6-(3-chlorophenyl)-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine; and
- 35 (S)-1-Benzyl-2-[6-benzyl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.

- 5 By the term "aryl" as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 1 to 14 carbon atoms and optionally containing from one to five heteroatoms, provided that when the number of carbon atoms is 1 the aromatic ring contains at least four heteroatoms, when the number of carbon atoms is 2 the aromatic ring contains at least three heteroatoms,
- 10 when the number of carbons is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.

By the term "C₁-C₁₂aryl" as used herein, unless otherwise defined, is meant phenyl, naphthalene, 3,4-methylenedioxyphenyl, pyridine, biphenyl, indazole, quinoline, isoquinoline, 7-azaindole, pyrimidine, quinazoline, thiophene, furan, pyrrole, pyrazole, imidazole, benzothiophene and tetrazole.

The term "substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has one or more substituents selected from the group consisting of: -CO₂R²⁰, aryl, -C(O)NHS(O)₂R²⁰, -NHS(O)₂R²⁰, hydroxyalkyl, alkoxy, -C(O)NR²¹R²², acyloxy, alkyl, amino, methylamino, dimethylamino, N-acylamino, hydroxy, -(CH₂)_gC(O)OR²³, -S(O)_nR²³, nitro, tetrazole, cyano, oxo, halogen, and trifluoromethyl, where g is 0-6, R²³ is hydrogen or alkyl, R²⁰ is selected form hydrogen, C₁-C₄alkyl, aryl and trifluoromethyl, and R²¹ and R²² are independently selected form hydrogen, C₁-C₄alkyl, aryl and trifluoromethyl, and n is 0-2.

By the term "alkoxy" as used herein is meant -Oalkyl where alkyl is as described herein including -OCH₃ and -OC(CH₃)₂CH₃.

The term "cycloalkyl" as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C₃-C₁₂.

- 30 Examples of cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, 4-hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl 4-methoxycyclohexyl, 4-methoxycyclohexyl, 4-carboxycyclohexyl, cyclopropyl and cyclopentyl.

- 35 The term "heterocycle," as used herein, unless otherwise defined, is meant a cyclic or polycyclic, non-aromatic, three-, four-, five-, six-, or seven-membered ring containing at least one atom, selected from the group consisting of oxygen,

nitrogen, and sulfur. The five-membered rings have zero or one double bond and the six- and seven-membered rings have zero, one, or two double bonds.

Examples of heterocyclic groups as used herein include: dihydroisoindolyl, dihydroisoquinolinyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl.

By the term "acyloxy" as used herein is meant -OC(O)alkyl where alkyl is as described herein. Examples of acyloxy substituents as used herein include: -OC(O)CH₃, -OC(O)CH(CH₃)₂ and -OC(O)(CH₂)₃CH₃.

10 By the term "N-acylamino" as used herein is meant -N(H)C(O)alkyl, where alkyl is as described herein. Examples of N-acylamino substituents as used herein include: -N(H)C(O)CH₃, -N(H)C(O)CH(CH₃)₂ and -N(H)C(O)(CH₂)₃CH₃.

15 By the term "aryloxy" as used herein is meant -Oaryl where aryl is phenyl, naphthyl, 3,4-methylenedioxyphenyl, pyridyl or biphenyl optionally substituted with one or more substituents selected from the group consisting of: alkyl, hydroxyalkyl, alkoxy, trifluoromethyl, acyloxy, amino, N-acylamino, hydroxy, -(CH₂)_gC(O)OR²⁵, -S(O)_nR²⁵, nitro, cyano, halogen and protected -OH, where g is 0-6, R²⁵ is hydrogen or alkyl, and n is 0-2. Examples of aryloxy substituents as used herein include: phenoxy, 4-fluorophenoxy and biphenyloxy.

20 By the term "heteroatom" as used herein is meant oxygen, nitrogen or sulfur.

By the term "halogen" as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.

25 By the term "alkyl" and derivatives thereof and in all carbon chains as used herein is meant a linear or branched, saturated or unsaturated hydrocarbon chain, and unless otherwise defined, the carbon chain will contain from 1 to 6 carbon atoms. Examples of alkyl substituents as used herein include: -CH₃, -CH₂-CH₃, -CH₂-CH₂-CH₃, -CH(CH₃)₂, -C(CH₃)₃, -(CH₂)₃-CH₃, -CH₂-CH(CH₃)₂, -CH(CH₃)-CH₂-CH₃, -CH=CH₂, and -C≡C-CH₃.

30 By the term "treating" and derivatives thereof as used herein, is meant prophylactic and therapeutic therapy.


All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth.


35 Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention. Where a -COOH or -OH group is present, pharmaceutically acceptable esters can be employed, for

example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics, for use as sustained release or prodrug formulations.

- 5 The novel compounds of Formulas I and II are prepared as shown in Schemes I and II below, or by analogous methods, wherein the 'L' and 'R' substituents are as defined in Formulas I and II respectively and provided that the 'L' and 'R' substituents do not include any such substituents that render inoperative the processes of Schemes I or II. All of the starting materials are commercially 10 available or are readily made from commercially available starting materials by those of skill in the art.

SCHEME 1



SCHEME 2

5

By the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of an AKT inhibiting compound, as described herein, and a further

10 active ingredient or ingredients, known to be useful in the treatment of cancer, including chemotherapy and radiation treatment, or to be useful in the treatment of arthritis. The term further active ingredient or ingredients, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for cancer or
 15 arthritis. Preferably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.

20 Examples of a further active ingredient or ingredients for use in combination with the presently invented AKT inhibiting compounds are chemotherapeutic agents.

Because the pharmaceutically active compounds of the present invention
 25 are active as AKT inhibitors they exhibit therapeutic utility in treating cancer and arthritis.

Suitably, the present invention relates to a method for treating or lessening the severity of a cancer.

Suitably, the present invention relates to a method for treating or lessening the severity of a cancer selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

Suitably, the present invention relates to a method for treating or lessening the severity of a cancer selected from ovarian, pancreatic and prostate.

Isolation and Purification of His-tagged AKT1 (aa 136-480)

10

Insect cells expressing His-tagged AKT1 (aa 136-480) were lysed in 25 mM HEPES, 100 mM NaCl, 20 mM imidazole; pH 7.5 using a polytron (5 mLs lysis buffer/g cells). Cell debris was removed by centrifuging at 28,000 x g for 30 minutes. The supernatant was filtered through a 4.5-micron filter then loaded onto 15 a nickel-chelating column pre-equilibrated with lysis buffer. The column was washed with 5 column volumes (CV) of lysis buffer then with 5 CV of 20% buffer B, where buffer B is 25 mM HEPES, 100 mM NaCl, 300 mM imidazole; pH 7.5. His-tagged AKT1 (aa 136-480) was eluted with a 20-100% linear gradient of buffer B over 10 CV. His-tagged AKT1 (136-480) eluting fractions were pooled and diluted 20 3-fold with buffer C, where buffer C is 25 mM HEPES, pH 7.5. The sample was then chromatographed over a Q-Sepharose HP column pre-equilibrated with buffer C. The column was washed with 5 CV of buffer C then step eluted with 5 CV 10%D, 5 CV 20% D, 5 CV 30% D, 5 CV 50% D and 5 CV of 100% D; where buffer D is 25 mM HEPES, 1000 mM NaCl; pH 7.5. His-tagged AKT1 (aa 136-480) 25 containing fractions were pooled and concentrated in a 10-kDa molecular weight cutoff concentrator. His-tagged AKT1 (aa 136-480) was chromatographed over a Superdex 75 gel filtration column pre-equilibrated with 25 mM HEPES, 200 mM NaCl, 1 mM DTT; pH 7.5. His-tagged AKT1 (aa 136-480) fractions were examined using SDS-PAGE and mass spec. The protein was pooled, concentrated and 30 frozen at -80C.

His-tagged AKT2 (aa 138-481) and His-tagged AKT3 (aa 135-479) were isolated and purified in a similar fashion.

35

Compounds of the invention are tested for potency as AKT inhibitors by known methods, such as described in International Application No. PCT/US02/10880.

5 The pharmaceutically active compounds within the scope of this invention are useful as AKT inhibitors in mammals, particularly humans, in need thereof.

The present invention therefore provides a method of treating cancer, arthritis and other conditions requiring AKT inhibition, which comprises administering an effective compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof. The compounds of Formula (I) 10 also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as Akt inhibitors. The drug may be administered to a patient in need thereof by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.

15 The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid;. Liquid carriers include 20 syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft 25 gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.

30 The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.

Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active 35 compound, preferably 0.001 - 50 mg/kg. When treating a human patient in need of an Akt inhibitor, the selected dose is administered preferably from 1-6 times daily, orally or parenterally. Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units

for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.

5 Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular Akt inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of
10 administration.

The method of this invention of inducing Akt inhibitory activity in mammals, including humans, comprises administering to a subject in need of such activity an effective Akt inhibiting amount of a pharmaceutically active compound of the present invention.

15 The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use as an Akt inhibitor.

The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in therapy.

20 The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating cancer.

The invention also provides for the use of a compound of Formula (I) in the manufacture of a medicament for use in treating arthritis.

25 The invention also provides for a pharmaceutical composition for use as an Akt inhibitor which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.

The invention also provides for a pharmaceutical composition for use in the treatment of cancer which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.

30 The invention also provides for a pharmaceutical composition for use in treating arthritis which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.

No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

35 In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat cancer or arthritis, or compounds known to have utility when used in combination with an Akt inhibitor.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and 5 not a limitation of the scope of the present invention in any way.

Experimental Details

The compounds of Examples 1 to 10 are readily made according to
10 Schemes I or II or by analogous methods.

Example 1

Preparation of (S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine

a) ((S)-1-Hydroxymethyl-2-phenyl-ethyl)-carbamic acid *tert*-butyl ester

Saturated NaHCO₃ aqueous solution (3 mL) was added to a solution of (-)-phenylalaninol (1.007 g, 6.66 mmol) and di-*t*-butyl dicarbonate (2.18 g, 9.99 mmol) in CH₂Cl₂ and the resulting mixture was stirred at room temperature for 3 h. The reaction was complete indicated by TLC. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (2 times). The combined the organic layers were dried (Na₂SO₄), concentrated, and the residue was purified by flash column chromatography (hexane/EtOAc 3:1) to give 1.64 g (98%) white solid.

25

b) 3-Bromo-2-chloro-5-((S)-2-methyl-3-phenyl-propoxy)-pyridine

DEAD (0.30 mL, 1.87 mmol) was added to a solution of 4-bromo-5-chloro-3-hydroxypyridine (243 mg, 1.17 mmol, Koch, V. Schnatterer, S. *Synthesis*, **1990**, 499-501), compound of Example 1 (a) (440 mg, 1.80 mmol) and Ph₃P (460 mg, 1.80 mmol) in THF (10 mL) at 0 °C. The resulting mixture was warmed up to room temperature and stirred for 1 h. The reaction was complete indicated by TLC. The reaction mixture was concentrated and the residue was purified by flash column chromatography (hexane/EtOAc 9:1) to give 450 mg (87%) white solid.

35 c) 3-Methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-indazole-1-carboxylic acid *tert*-butyl ester

A mixture of N-Boc-3-methyl-5-bromoindazole (1.11 g, 3.58 mmol), bis(pinacola)diboron (1.0 g, 3.94 mmol), KOAc (527 mg, 5.37 mmol), Pd₂dba₃ (49 mg, 0.054 mmol) and PCy₃ (72 mg, 0.26 mmol) in dioxane (21.5 mL) was purged with N₂ and heated at 80 °C under N₂ for 24 h. The reaction mixture was filtered through celite, which was rinsed with EtOAc. The combined filtrates were concentrated and the residue was purified by flash column chromatography (hexane/EtOAc 9:1) to give 1.046 g (74%) of light yellow solid.

d) 5-[5-((S)-2-*tert*-Butoxycarbonylamino-3-phenyl-propoxy)-2-chloro-pyridin-3-yl]-

10 3-methyl-indazole-1- carboxylic acid *tert*-butyl ester

A mixture of compound Example 1(b) (550 mg, 1.24 mmol), compound of Example 1(c) (550 mg, 1.53 mmol), (Ph₃P)₄Pd (143 mg, 0.12 mmol), 2N Na₂CO₃ aqueous solution (0.84 mL) and 1,4-dioxane (10 mL) was degassed and heated at 100 °C under N₂ overnight. The reaction mixture was filtered through celite, which was rinsed with EtOAc. The combined filtrates were concentrated and the residue was purified by flash column chromatography (hexane/EtOAc 3:1 to 1:1) to give 585 mg (80%) of light yellow solid.

e) {(S)-1-Benzyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethyl}-

20 carbamic acid *tert*-butyl ester

A mixture of compound of Example 1(d) (196 mg, 0.33 mmol), phenylboronic acid (80.6 mg, 0.66 mmol), (Ph₃P)₄Pd (19 mg, 0.016 mmol), 2N Na₂CO₃ aqueous solution (0.73 mL) and 1,4-dioxane (3 mL) was degassed and irradiated under micro wave at 160 °C for 20 min. The reaction mixture was filtered through celite, which was rinsed with EtOAc. The combined the filtrates were concentrated and the residue was purified by flash column chromatography (hexane/EtOAc 3:1 to 1:1) to give 101 mg (57%) of light yellow solid.

f) (S)-1-Benzyl-2-[5-(3-methyl-1*H*-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-

30 ethylamine

A solution of Example 1(e) and 0.5 mL of TFA in CH₂Cl₂ was stirred at room temperature for 30 min, diluted with toluene and concentrated. The residue was taken up into DMSO and purified on reversed phase HPLC (MeCN, H₂O, 0.1% TFA) to give 78mg of white solid. (78%) ¹H NMR (CD₃OD, 400 MHz) δ 8.49 (d, J = 2.8 Hz, 1H), 7.92 (d, J = 2.8 Hz, 1H), 7.66 (d, J = 0.7 Hz, 1H), 7.40-7.32 (m, 11H), 7.11 (dd, J = 8.7, 1.6 Hz), 4.46 (dd, J = 10.6, 3.0 Hz, 1H), 4.31 (dd, J = 10.6, 5.6

Hz, 1H), 4.03-3.95 (m, 1H), 3.19 (d, $J = 7.4$ Hz, 2H), 2.50 (s, 3H); MS (M+H): 435.2

Example 2

5

Preparation of (S)-1-Benzyl-2-[6-furan-2-yl-5-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine

Following the procedure of Example 1(a)-1(f), except substituting 2-furanboronic acid for phenylboronic acid, the title compound was prepared. ^1H NMR (CD_3OD , 400 MHz) δ 8.40 (d, $J = 2.8$ Hz, 1H), 7.72 (dd, $J = 1.4, 0.9$ Hz, 1H), 7.61 (d, $J = 2.8$ Hz, 1H), 7.56-7.54 (m, 2H), 7.41-7.31 (m, 7H), 7.28 (dd, $J = 8.6, 1.6$ Hz, 1H), 6.36 (dd, $J = 3.5, 1.8$ Hz, 1H), 5.91 (dd, $J = 3.5, 0.6$ Hz, 1H), 4.48 (dd, $J = 10.6, 3.0$ Hz, 1H), 4.23 (dd, $J = 10.6, 5.6$ Hz, 1H), 4.00-3.90 (m, 1H), 3.16 (d, $J = 7.6$ Hz, 2H), 2.58 (s, 3H); MS (M+H): 425.2

10

Example 3

Preparation of (S)-1-Benzyl-2-[5,6-bis-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine

20

Following the procedure of Example 1(a)-1(f), except substituting 3-methyl-1H-indazol-5-ylboronic acid for phenylboronic acid, the title compound was prepared. ^1H NMR (CD_3OD , 400 MHz) δ 8.46 (s, 1H), 7.81-7.78 (m, 2H), 7.71 (s, 1H), 7.40-7.27 (m, 13H), 7.19 (dd, $J = 8.7, 1.5$ Hz, 1H), 7.07 (d, $J = 8.6$ Hz, 1H), 4.45-4.42 (m, 1H), 4.30-4.25 (m, 1H), 4.01-3.92 (m, 1H), 3.19 (d, $J = 6.7, 2$ H), 2.50 (s, 3H), 2.45 (s, 3H) MS (M+H): 489.2

25

Example 4

Preparation of (S)-1-Benzyl-2-[6-thiophen-2-yl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine

30

Following the procedure of Example 1(a)-1(f), except substituting 2-thiopheneboronic acid for phenylboronic acid, the title compound was prepared. ^1H NMR (CD_3OD , 400 MHz) δ 8.47 (d, 1H), 7.90 (s, 1H), 7.68 (d, 1H), 7.48-7.30 (m, 8H), 7.17 (d, 1H), 6.88 (dd, 1H), 4.45 (m, 1H), 4.32 (m, 1H), 4.00 (m, 1H), 3.19 (d, 2H), 2.54 (s, 3H). MS (M+H): 441.2

Example 5Preparation of (S)-1-Benzyl-2-[6-(4-chlorophenyl)-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

5 Following the procedure of Example 1(a)-1(f), except substituting 4-chlorophenylboronic acid for phenylboronic acid, the title compound was prepared.
¹H NMR (CD₃OD, 400 MHz) δ 8.46 (d, 1H), 7.68 (dd, 2H), 7.40-7.29 (m, 6H), 7.22 (m, 4H), 7.06 (m, 1H), 4.40 (m, 1H), 4.25 (m, 1H), 3.97 (m, 1H), 3.19 (d, 2H), 2.53 (s, 3H). MS (M+H): 469.2

10

Example 6Preparation of (S)-1-Benzyl-2-[6-(3-chlorophenyl)-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

15 Following the procedure of Example 1(a)-1(f), except substituting 3-chlorophenylboronic acid for phenylboronic acid, the title compound was prepared.
¹H NMR (CD₃OD, 400 MHz) δ 8.42 (d, 1H), 7.65 (s, 1H), 7.60 (s, 1H), 7.42-7.28 (m, 8H), 7.19 (t, 1H), 7.08 (m, 2H), 4.39 (m, 1H), 4.26 (m, 1H), 3.97 (m, 1H), 3.18 (d, 2H), 2.50 (s, 3H). MS (M+H): 469.2

20

Example 7Preparation of (S)-1-Benzyl-2-[6-benzyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

25 a) {(S)-1-Benzyl-2-[6-benzyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid benzyl ester

A mixture of 1(d) (35 mg, 0.059 mmol), BrZnPh (0.59 mL, 0.5 M in THF), and Pd(Ph₃P)₄ (6.8 mg, 0.0059 mmol) was purged with N₂, stirred at 75 °C overnight and cooled to room temperature. Saturated NH₄Cl aqueous solution was added and the aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na₂SO₄), concentrated and the residue was purified by flash column chromatography (hexane/EtOAc 1:1) to give 18mg mixture 7(a) and {(S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid benzyl ester.

30

b) (S)-1-Benzyl-2-[6-benzyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine

A mixture of 7(a) and {(s)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid benzyl ester (18 mg), 10% Pd/C (5 mg) and 0.5 mL of MeOH was stirred under a balloon pressure of H₂ overnight. The reaction mixture was filtered through celite, which was rinsed with MeOH. The combined filtrates

5 were concentrated and the residue was purified by reversed phase HPLC (MeCN, H₂O, 0.1% TFA) to give 2.3 mg of the title compound. ¹H NMR (CD₃OD, 400 MHz) δ 8.40 (d, 1H), 7.62 (dd, 1H), 7.53 (d, 1H), 7.46 (s, 1H), 7.40-7.27 (m, 6H), 7.18 (m, 3H), 6.88 (m, 2H), 4.35 (m, 1H), 4.20 (m, 3H), 3.82 (m, 1H), 3.13 (d, 2H), 2.49 (s, 3H), MS (M+H): 449.2

10

Example 8 Capsule Composition

An oral dosage form for administering the present invention is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.

<u>INGREDIENTS</u>	<u>AMOUNTS</u>
(S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine	25 mg
Lactose	55 mg
Talc	16 mg
Magnesium Stearate	4 mg

20

Example 9 - Injectable Parenteral Composition

An injectable form for administering the present invention is produced by stirring 1.5% by weight of (S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine in 10% by volume propylene glycol in water.

25

Example 10 - Tablet Composition

The sucrose, calcium sulfate dihydrate and an Akt inhibitor as shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid;, screened and compressed into a tablet.

Table II

<u>INGREDIENTS</u>	<u>AMOUNTS</u>
(S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine	20 mg
calcium sulfate dihydrate	30 mg
sucrose	4 mg
starch	2 mg
talc	1 mg
stearic acid	0.5 mg


5

While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the 10 scope of the following claims is reserved.

What is claimed is:

1. A compound of Formula (I):

5



(I)

wherein:

L¹ is selected from the group consisting of a bond, -O-, -N(R⁵)-, -S-, -S(O)-,
10 -S(O₂)-, alkyl, and -N(R⁵)C(O)-;

L² is selected from the group consisting of a bond, -O-, -N(R⁵)-, -
N(R⁵)C(O)-, -S-, -S(O)-, -S(O₂)-, and -C(O)N(R⁵)-;

15 L³ is alkyl, wherein the alkyl is substituted with one or two substituents
independently selected from the group consisting of amino, oxo, and hydroxy;

L⁶ is selected from the group consisting of a bond, -O-, -N(R⁵)-, -S-, -S(O)-,
-S(O₂)-, alkyl, and -N(R⁵)C(O)-;

20

R¹ is selected from the group consisting of aryl, substituted aryl,
heterocycle and substituted heterocycle;

25 R² is selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
heterocycle, substituted heterocycle, and a cyclic or polycyclic aromatic ring
containing from 3 to 16 carbon atoms and optionally containing one or more
heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring
contains at least two heteroatoms and when the number of carbon atoms is 4 the
aromatic ring contains at least one heteroatom, and optionally substituted with one
30 or more substituents selected from the group consisting of: alkyl, substituted alkyl,
aryl, substituted cycloalkyl, substituted aryl, aryloxy, oxo, hydroxy, alkoxy,
cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, -C(O)OR⁷, -
C(O)NR⁸R⁹, -S(O)₂NR⁸R⁹, and -S(O)_nR⁷,

where n is 0-2,

R⁷ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and

R⁸ and R⁹ are independently hydrogen, cycloalkyl, C₁-C₁₂aryl,

5 substituted cycloalkyl, substituted C₁-C₁₂aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of:

alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, -C(O)OR¹⁰, -S(O)_nR¹⁰, -C(O)NR¹⁰R¹¹, -S(O)₂NR¹⁰R¹¹, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, aryl, and substituted aryl,

10 or R⁸ and R⁹ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where the ring is optionally substituted with one or more substituents selected from amino, methylamino and dimethylamino,

15 where R¹⁰ and R¹¹ are independently hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and n is 0-2;

R^3 and R^6 are independently selected from the group consisting of


hydrogen, aryl, substituted aryl, and arylalkoxy; provided that when L¹ and L² are bonds, at least one of R³ and R⁶ is other than hydrogen;

R^4 is selected from the group consisting of hydrogen and halo; and

25 R⁵ is selected from the group consisting of hydrogen and alkyl.

2. A pharmaceutically acceptable salt, hydrate, solvate or ester of a compound of Formula (I), as described in claim 1.

30 3. A compound of Claim 1 represented by the following Formula
(II):



(II) (II)

wherein:

L⁴ is selected from the group consisting of a bond, and -O-;

5 L⁵ is alkyl, wherein the alkyl is substituted with one or two substituents independently selected from the group consisting of amino, oxo, and hydroxy;

R¹⁴ is selected from the group consisting of C₁-C₁₂aryl, and substituted C₁-C₁₂aryl;

10 R¹⁵ is selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, C₁-C₁₂aryl and C₁-C₁₂aryl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, aryloxy, hydroxy, alkoxy, acyloxy, amino, N-acylamino, nitro, 15 cyano and halogen;

R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, C₁-C₁₂aryl and substituted C₁-C₁₂aryl.

20 4. A pharmaceutically acceptable salt, hydrate, solvate or ester of a compound of Formula (II), as described in claim 3.

25 5. A method of treating or lessening the severity of a disease or condition selected from cancer and arthritis, wherein said method comprises the administration of an effective amount of a compound of Formula I, as described in claim 1.

30 6. A method of treating or lessening the severity of a disease or condition selected from cancer and arthritis, wherein said method comprises the administration of an effective amount of a compound of Formula I, as described in claim 2.

35 7. The method according to claim 5 wherein said cancer is selected from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck,

kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and thyroid.

8. The method according to claim 6 wherein said cancer is selected
5 from brain (gliomas), glioblastomas, Bannayan-Zonana syndrome,
Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck,
kidney, lung, liver, melanoma, ovarian, pancreatic, prostate, sarcoma and
thyroid.

10 9. A compound selected from:

(S)-1-Benzyl-2-[5-(3-methyl-1H-indazol-5-yl)-6-phenyl-pyridin-3-yloxy]-ethylamine;

15 (S)-1-Benzyl-2-[6-furan-2-yl-5-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-
ethylamine;

(S)-1-Benzyl-2-[5,6-bis-(3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine;

20 (S)-1-Benzyl-2-[6-thiophen-2yl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-
ethylamine;

(S)-1-Benzyl-2-[6-(4-chlorophenyl)-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-
ethylamine;

25 (S)-1-Benzyl-2-[6-(3-chlorophenyl)-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-
ethylamine; and

(S)-1-Benzyl-2-[6-benzyl-5- (3-methyl-1H-indazol-5-yl) -pyridin-3-yloxy]-ethylamine.

30 10. A pharmaceutically acceptable salt, hydrate, solvate or ester of a
compound of Formula (II), as described in claim 9.

ABSTRACT OF THE DISCLOSURE

Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.